Role of tyrosine kinases in lymphocyte activation: targets for drug intervention.
Recent developments in our understanding of lymphocyte receptor-associated signalling events have offered many new potential targets for modifying antigen and cytokine receptor signalling events in immune-related diseases such as allergy, autoimmunity and transplant rejection. As discussed below, these targets are largely tissue-restricted and are functionally confined to a limited set of receptors. Therefore, it is anticipated that selective inhibitors of these signalling events would offer safe and effective therapies for immunologically-based diseases. First, we review T and B cell antigen receptor signalling as targets for inhibiting lymphocyte responses. Second, targets in lymphocyte cytokine receptor signalling pathways are discussed. Finally, we review strategies for inhibition of receptor signalling.
Hanke
J H
JH
Pfizer Central Research, Groton, CT 06340, USA.
Pollok
B A
BA
Changelian
P S
PS
D000818:Animals; D015703:Antigens, CD / Q000502:physiology; D006801:Humans; D053613:Janus Kinase 1; D008213:Lymphocyte Activation; D011505:Protein-Tyrosine Kinases / Q000502:physiology*; D011947:Receptors, Antigen, B-Cell / Q000502:physiology; D018123:Receptors, Interleukin / Q000502:physiology; D015375:Receptors, Interleukin-2 / Q000502:physiology; D019948:Receptors, Interleukin-4; D015398:Signal Transduction
D015703:Antigens, CD; D011947:Receptors, Antigen, B-Cell; D018123:Receptors, Interleukin; D015375:Receptors, Interleukin-2; D019948:Receptors, Interleukin-4; D011505:Protein-Tyrosine Kinases; C507904:JAK1 protein, human; D053613:Janus Kinase 1